"Atenolol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
| Descriptor ID |
D001262
|
| MeSH Number(s) |
D02.033.100.624.698.070 D02.033.755.624.698.070 D02.092.063.624.698.070
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Atenolol".
Below are MeSH descriptors whose meaning is more specific than "Atenolol".
This graph shows the total number of publications written about "Atenolol" by people in this website by year, and whether "Atenolol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Atenolol" by people in Profiles.
-
Shafi T, Appel LJ, Miller ER, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension. 2008 Dec; 52(6):1022-9.
-
Matsui Y, Eguchi K, Shibasaki S, Ishikawa J, Hoshide S, Pickering TG, Shimada K, Kario K. Monitoring of the central pulse pressure is useful for detecting cardiac overload during antiadrenergic treatment: the Japan Morning Surge 1 study. J Hypertens. 2008 Oct; 26(10):1928-34.
-
Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, Mancia G, Kowey P, Zhou Q, Champion A, Pepine CJ. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Am Heart J. 2008 Aug; 156(2):241-7.
-
Medei EH, Nascimento JH, Pedrosa RC, Barcellos L, Masuda MO, Sicouri S, Elizari MV, de Carvalho AC. Antibodies with beta-adrenergic activity from chronic chagasic patients modulate the QT interval and M cell action potential duration. Europace. 2008 Jul; 10(7):868-76.
-
Pepine CJ, Kowey PR, Kupfer S, Kolloch RE, Benetos A, Mancia G, Coca A, Cooper-DeHoff RM, Handberg E, Gaxiola E, Sleight P, Conti CR, Hewkin AC, Tavazzi L. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol. 2006 Feb 07; 47(3):547-51.
-
Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahl?f B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol. 2005 Dec 01; 96(11):1530-6.
-
Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 03; 290(21):2805-16.
-
Lyons CW, Colmorgen GH. Medical management of pheochromocytoma in pregnancy. Obstet Gynecol. 1988 Sep; 72(3 Pt 2):450-1.